NHS prescribing data
Before an opportunity is taken it has to be sized. MPA holds every medicine prescribed in the community and used in hospitals in England, by molecule, presentation and product, so the demand for a product, where it is used, who supplies it and how it is moving can be seen in depth.
What it holds
- Every medicine prescribed in the community and used in hospitals in England.
- Quantities, prescription items and value at list price, by molecule, presentation and product.
- Rolling twelve months, calendar years and financial years, with change on the prior year.
- The latest price per unit, brand share and hospital share.
- Markets
- England (NHS community prescribing and hospital use).
Who uses it, and why
- Generics and biosimilar companiesTo see how big an opportunity is: how much is prescribed, where, and at what value, before the field crowds.
- Originators, brand and portfolio teamsTo see how demand is moving for their products and the ones they compete with.
- Procurement and buyersNHS volumes and value for England, beside the published prices across Europe.
- Consultancies and advisersTo size demand in England for a market entry study, a due diligence or a valuation.
Questions it answers
How much of this product does the NHS in England use?
Where is it used: in the community or in hospitals?
What is it worth at list price, and how has that changed on the prior year?
How much is still the brand, and how much is generic?
Which presentations and products make up the demand, and who supplies them?
What is the latest price per unit?
How it is searched
Assessing a product
- 1Search by molecule, presentation or product.
- 2Read quantities, items and value over the rolling twelve months and the calendar and financial years.
- 3See the change on the prior year, the brand share and the hospital share.
- 4If you also subscribe to prices, compare with the published list prices across Europe.
Finding opportunities
- 1Work through a whole list of products in one go to see which carry the most volume and value.
- 2Add the patent and SPC position to see what the products opening up are worth.
- 3Add product licences to see how many suppliers are already in each.
- 4Follow the trends to see where demand is growing or falling.
Expert support, included
How a demand figure becomes an opportunity once protection, prices and the number of suppliers are taken into account is the kind of question we answer as part of every subscription.
What to read first
All resources- ExplainersWhy the expiry date is not the launch date in Europe (and what is)A patent or SPC expiry date on a register is the start of the answer, not the end. Between it and the first generic pack on a shelf sit secondary patents, paediatric extensions, regulatory clocks, pricing procedures and litigation, and they differ by country. The steps, in order, and where each one can move the date.
- ExplainersFrom SPC expiry to first generic supplyThe exclusivity date is when a generic may be sold, not when it is on the shelf. What has to be in place by that day: the authorisation filed at year eight, pricing and reimbursement country by country, tender calendars, packs, stock and the patent position, and why first supply lands within days in some markets and a year later in others.
- PricesList price versus net priceThe price on a national list is rarely the price anyone pays. Confidential rebates, managed-entry agreements, clawbacks, tender prices and wholesale discounts all sit between the two. What the gap is made of, where it is largest, and how to work with published prices when the real ones are hidden.
- Regulatory changesUK branded medicines pricing after the US dealThe 2025 repayment rate of 22.9% under the voluntary scheme set off a crisis that ended in a UK–US pricing arrangement in December 2025. The 2026 voluntary rate is 14.5% plus a 1% levy, capped at 15% to 2028; the statutory scheme fell from 24.3% to 16.5% on 1 July 2026; NICE's threshold rose to £25,000–35,000 per QALY in April 2026; and NHS net prices for new medicines are to rise. What each piece does, and what it means for the EU–UK price differential.
- Case notesSkinny labelsLeaving the patented indication off the label is necessary but not sufficient. Where prescribing and dispensing are by substance, or supply is by a tender that covers every use, the generic's product will reach the patented use whatever the label says, and the courts ask two further questions: did the supplier know that would happen, and what did it do to prevent it. The UK Supreme Court's pregabalin ruling is the most label-friendly answer; the Dutch and German courts have required active measures and have enjoined companies that only relabelled; the UPC in 2025 made knowledge plus conduct the test.
- ExplainersWhat breaks when you track loss of exclusivity in a spreadsheet, and what to do insteadMost companies start with a spreadsheet of products and expiry dates, and most of those spreadsheets are wrong within a year. The seven ways they fail, from one row per product to dates typed rather than calculated, and the structure, rules and review cadence that keep a loss-of-exclusivity list honest, whether it stays in Excel or not.
See MPA Search in action
A free online demonstration with our team, with time for your questions.